Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
TinniStop appears to have been a small U.S. consumer health brand marketing an over-the-counter homeopathic tablet for tinnitus symptom relief, with additional labeling for vertigo-related dizziness and nausea. Publicly available evidence links the brand to Peerless Homeopathic, with product listings on DailyMed and other NDC-label databases identifying the product as a homeopathic oral tablet containing causticum, conium maculatum, and cocculus indicus. A 2017 press release described TinniStop as a patent-pending natural remedy founded by Wayne Josephson and manufactured in an FDA-registered U.S. laboratory. However, there is little evidence of a broader operating biotech or pharmaceutical company, clinical pipeline, financing history, or ongoing corporate activity. Based on the available information, TinniStop is best understood as a branded homeopathic OTC product/business rather than a conventional life sciences drug developer.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on TinniStop.